-$0.32 EPS Expected for ReWalk Robotics Ltd (RWLK) This Quarter
Wall Street brokerages predict that ReWalk Robotics Ltd (NASDAQ:RWLK) will report earnings of ($0.32) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for ReWalk Robotics’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). ReWalk Robotics reported earnings of ($0.52) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The business is scheduled to report its next quarterly earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that ReWalk Robotics will report full year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.31) to ($1.17). For the next financial year, analysts expect that the firm will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.53) to ($1.27). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow ReWalk Robotics.
ReWalk Robotics (NASDAQ:RWLK) last announced its earnings results on Thursday, August 3rd. The medical device company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.06. The company had revenue of $2.01 million during the quarter, compared to analysts’ expectations of $1.71 million. ReWalk Robotics had a negative net margin of 389.13% and a negative return on equity of 528.26%. ReWalk Robotics’s quarterly revenue was up 145.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.64) earnings per share.
RWLK has been the topic of a number of recent research reports. Zacks Investment Research raised ReWalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Thursday, May 11th. Canaccord Genuity reissued a “buy” rating on shares of ReWalk Robotics in a report on Monday, June 12th. Finally, Oppenheimer Holdings, Inc. set a $4.00 target price on ReWalk Robotics and gave the company a “buy” rating in a report on Friday, August 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $4.00.
In other ReWalk Robotics news, major shareholder Scp Vitalife Partners Ii Lp sold 65,218 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $3.05, for a total value of $198,914.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Wayne Weisman sold 87,000 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $3.05, for a total value of $265,350.00. The disclosure for this sale can be found here. In the last three months, insiders sold 198,637 shares of company stock worth $603,339. 13.70% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in ReWalk Robotics stock. Renaissance Technologies LLC increased its position in ReWalk Robotics Ltd (NASDAQ:RWLK) by 61.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 78,600 shares of the medical device company’s stock after buying an additional 30,000 shares during the period. Renaissance Technologies LLC owned approximately 0.48% of ReWalk Robotics worth $165,000 at the end of the most recent reporting period. 4.69% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ReWalk Robotics (NASDAQ:RWLK) traded up 11.83% during midday trading on Tuesday, hitting $1.65. 776,064 shares of the stock were exchanged. The firm’s market capitalization is $27.51 million. ReWalk Robotics has a 1-year low of $1.10 and a 1-year high of $6.50. The stock’s 50-day moving average price is $1.42 and its 200-day moving average price is $1.66.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related stocks with our FREE daily email newsletter.